These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 38254784)

  • 21. Tumor microenvironment pH-responsive pentagonal gold prism-based nanoplatform for multimodal imaging and combined therapy of castration-resistant prostate cancer.
    Tan H; Liu Y; Hou N; Cui S; Liu B; Fan S; Yu G; Han C; Zheng D; Li W; Liu Y; Xu B; Wang Z; Cui D
    Acta Biomater; 2022 Mar; 141():408-417. PubMed ID: 35032718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor microenvironment deconvolution identifies cell-type-independent aberrant DNA methylation and gene expression in prostate cancer.
    Reynolds SR; Zhang Z; Salas LA; Christensen BC
    Clin Epigenetics; 2024 Jan; 16(1):5. PubMed ID: 38173042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploiting Epigenetic Alterations in Prostate Cancer.
    Baumgart SJ; Haendler B
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28486411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic modifications in prostate cancer.
    Sugiura M; Sato H; Kanesaka M; Imamura Y; Sakamoto S; Ichikawa T; Kaneda A
    Int J Urol; 2021 Feb; 28(2):140-149. PubMed ID: 33111429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
    Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
    Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
    Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
    Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
    Cheng B; Lai Y; Huang H; Peng S; Tang C; Chen J; Luo T; Wu J; He H; Wang Q; Huang H
    Environ Toxicol; 2024 Feb; 39(2):927-941. PubMed ID: 37972062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic and epigenetic changes in human prostate cancer.
    Koochekpour S
    Iran Red Crescent Med J; 2011 Feb; 13(2):80-98. PubMed ID: 22737441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The genetics of neuroendocrine prostate cancers: a review of current and emerging candidates.
    Ather MH; Siddiqui T
    Appl Clin Genet; 2012; 5():105-10. PubMed ID: 23776386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer.
    Choi SYC; Ribeiro CF; Wang Y; Loda M; Plymate SR; Uo T
    Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcription Factors as Novel Therapeutic Targets and Drivers of Prostate Cancer Progression.
    Xie K; Tan K; Naylor MJ
    Front Oncol; 2022; 12():854151. PubMed ID: 35547880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic and Epitranscriptomic Control in Prostate Cancer.
    López J; Añazco-Guenkova AM; Monteagudo-García Ó; Blanco S
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapies for the treatment of advanced prostate cancer.
    Clarke JM; Armstrong AJ
    Curr Treat Options Oncol; 2013 Mar; 14(1):109-26. PubMed ID: 23322116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer.
    Mulvey A; Muggeo-Bertin E; Berthold DR; Herrera FG
    Front Immunol; 2022; 13():859785. PubMed ID: 35603186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic reprogramming during prostate cancer progression: A perspective from development.
    Goel S; Bhatia V; Biswas T; Ateeq B
    Semin Cancer Biol; 2022 Aug; 83():136-151. PubMed ID: 33545340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From Therapy Resistance to Targeted Therapies in Prostate Cancer.
    Moreira-Silva F; Henrique R; Jerónimo C
    Front Oncol; 2022; 12():877379. PubMed ID: 35686097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
    JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
    Saleh R; Toor SM; Sasidharan Nair V; Elkord E
    Front Immunol; 2020; 11():1469. PubMed ID: 32760400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.